AS

Alek Safarian

CEO at ALSA Ventures

London, England

Investor
VC
CEO

Invests in

Stages:

Seed
Pre-seed

Locations:

United Kingdom

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Skills

Clinical Trials
CRO
Pharmaceutical Industry
Regulatory Affairs
Clinical Development
Medical Devices
Strategy
Biotechnology
CTMS
Informatics
Medical Writing
Clinical Research
Mergers & Acquisitions
Infectious Diseases
Pharmacovigilance
Diabetes
Vaccines
GCP
Oncology
Sop

Education

Work Experience

ALSA Ventures

2018

  • CEO

    2018

Novotech

1996 - 2017

  • Member of the Board of Directors

    1996 - 2017

  • CEO

    1996 - 2017

    Executive responsibility for day to day operations of the company, setting strategy together with management team and board, executing on the company's growth strategy.

Marion Merrell Dow (now Sanofi-Aventis)

1990 - 1995

  • Head, Scientific Affairs, Asia-Pacific

    1990 - 1995

    Based in Sydney, headed the regulatory affairs function and post-marketing research in 11 countries in the Asia-Pacific including Australia, China, Korea, Taiwan, and Singapore. Left MMD just before merger with Hoechst Roussel to found Novotech.

Ciba-Geigy (now Novartis)

1988 - 1990

  • Regulatory Affairs Associate

    1988 - 1990